Stocktoria
Chemomab Therapeutics Ltd. CMMB
Chemomab Therapeutics Ltd. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($0.09); a green figure means the price is below it.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
P / E vs its own history
Chemomab Therapeutics Ltd. trades at about 106.7× earnings — above its 10-year norm (10-year range 22.4×–326.7×, median 86.1×).
Shaded band = 10-year range (22.4×–326.7×); dot = today's 106.7×.
Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Return on assets | -65.1% | -82.2% | -109.3% | -64.2% | -19.4% | -47.7% | -137.3% | -108.1% |
| Return on equity | -72.9% | -103.0% | -142.5% | -76.3% | -20.3% | -55.1% | -219.2% | -140.7% |
| Current ratio | 9.08 | 4.98 | 4.32 | 6.18 | 23.66 | 9.00 | 4.42 | 3.98 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.